Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy

被引：0

作者：

R. H. Enting

P. Portegies

机构：

[1] Department of Neurology,

[2] Academic Medical Center H2-214,undefined

[3] Meibergdreef 9,undefined

[4] 1105 AZ,undefined

[5] Amsterdam,undefined

[6] The Netherlands e-mail: P.Portegies@amc.uva.nl Tel.: +31-20-5663842 Fax: +31-20-6971438,undefined

来源：

Journal of Neurology | 2000年 / 247卷

关键词：

Key words Progressive multifocal leukoencephalopathy; Anti-HIV agents; Cytarabine; HIV infection;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We assessed survival in AIDS-related progressive multifocal leukoencephalopathy (PML) and the effect of cytarabine and antiretroviral therapy in a retrospective analysis of a series of consecutive 35 patients with AIDS-related PML in an academic AIDS referral center over ¶15 years. Treatment regimens consisted of highly active antiretroviral treatment (HAART), intravenous cytarabine, or both. Median survival after diagnosis in the overall series was 88 days. Patients with low CD4 cell count tended to have shorter survival. Seven patients (20%) had prolonged survival (> 1 year). Cytarabine did not affect survival. Seven patients were treated with HAART, which did not significantly improve survival. We conclude that the prognosis of AIDS-related PML is still poor, with a median survival of ¶3 months.

引用

页码：134 / 138

页数：4

共 50 条

[31] Progressive multifocal leukoencephalopathy despite immune recovery in a HIV/HCV co-infected patient
M. Hentzien
A. Guihot
Doé de Maindreville
T. Tabary
V. Brodard
V. Vieillard
H. Adle-Biassette
F. Bani-Sadr
Journal of NeuroVirology, 2020, 26 : 607 - 610
[32] Reduction of hematogenous infection in HIV positive patients following highly active antiretroviral therapy
Pedro-Botet, ML
Mòdol, JM
Vallés, X
Reynaga, E
Romeu, J
Juan, M
Sopena, N
Leal, MS
MEDICINA CLINICA, 2001, 116 (07): : 256 - 258
[33] Gynecomastia associated with highly active antiretroviral therapy
Manfredi, R
Calza, L
Chiodo, F
ANNALS OF PHARMACOTHERAPY, 2001, 35 (04) : 438 - 439
[34] AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy
Cheung, MC
Pantanowitz, L
Dezube, BJ
ONCOLOGIST, 2005, 10 (06) : 412 - 426
[35] Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy
Girardi, E
Antonucci, G
Vanacore, P
Palmieri, F
Matteelli, A
Iemoli, E
Carradori, S
Salassa, B
Pasticci, MB
Raviglione, MC
Ippolito, G
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (01) : 11 - 17
[36] Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy:: Secondary prophylaxis
Abgrall, S
Matheron, S
Le Moing, V
Dupont, C
Costagliola, D
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (02) : 151 - 158
[37] Vitamin A and Beta-Carotene Concentrations in Adults with HIV/AIDS on Highly Active Antiretroviral Therapy
Kaio, Daniella Junko
Carvalho Rondo, Patricia Helen
Pacheco Souza, Jose Maria
Firmino, Aline Vale
Luzia, Liania Alves
Segurado, Aluisio Augusto
JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, 2013, 59 (06) : 496 - 502
[38] Influence of highly-active antiretroviral therapy on the subgingival biofilm in HIV-infected patients
Jordan, Rainer A.
Lucaciu, Adrian
Zimmer, Stefan
JOURNAL OF INVESTIGATIVE AND CLINICAL DENTISTRY, 2016, 7 (01) : 65 - 71
[39] Clinical treatment outcomes of periodontal therapy in HIV-seropositive patients undergoing highly active antiretroviral therapy
Jordan, A. R.
Gaengler, P.
Joehren, H. -P.
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2006, 11 (06) : 232 - 235
[40] Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy
Lenner, R
Bregman, Z
Teirstein, AS
DePalo, L
CHEST, 2001, 119 (03) : 978 - 981

← 1 2 3 4 5 →